famotidine has been researched along with Adenocarcinoma in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 158 patients (155 early gastric cancers and three adenomas) were randomly assigned to the PPI group (omeprazole 20 mg/day) or H(2) RA group (famotidine 40 mg/day) in a prospective randomized controlled trial." | 5.16 | Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection. ( Fukui, H; Hori, K; Kim, Y; Kondo, T; Matsumoto, T; Miwa, H; Morita, T; Okugawa, T; Oshima, T; Sakurai, J; Tanaka, J; Tomita, T; Toyoshima, F; Watari, J; Yamasaki, T, 2012) |
| " Subjects underwent EMR with circumferential mucosal incision assisted by submucosal injection of sodium hyaluronate (EMRSH), followed by IV or oral (PO) administration of famotidine at a dosage of 40 mg/day for 2 days." | 2.71 | Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions. ( Ajibe, H; Hanatsuka, K; Hirasawa, T; Kawata, H; Kita, H; Osawa, H; Satoh, K; Satoh, Y; Sugano, K; Sunada, F; Sunada, K; Yamamoto, H; Yoshizawa, M, 2005) |
| "tumor growth, secondary lung metastasis and splenocyte cytotoxicity against YAC-1 lymphoma cells (51Cr release assay)." | 1.29 | Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis. ( Khoo, NK; Lala, PK; Saarloos, MN, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomita, T | 1 |
| Kim, Y | 1 |
| Yamasaki, T | 1 |
| Okugawa, T | 1 |
| Kondo, T | 1 |
| Toyoshima, F | 1 |
| Sakurai, J | 1 |
| Tanaka, J | 1 |
| Morita, T | 1 |
| Oshima, T | 1 |
| Fukui, H | 1 |
| Hori, K | 1 |
| Watari, J | 1 |
| Matsumoto, T | 1 |
| Miwa, H | 1 |
| Satoh, K | 1 |
| Yamamoto, H | 1 |
| Kawata, H | 1 |
| Osawa, H | 1 |
| Hanatsuka, K | 1 |
| Kita, H | 1 |
| Sunada, K | 1 |
| Hirasawa, T | 1 |
| Yoshizawa, M | 1 |
| Ajibe, H | 1 |
| Satoh, Y | 1 |
| Sunada, F | 1 |
| Sugano, K | 1 |
| Saarloos, MN | 1 |
| Khoo, NK | 1 |
| Lala, PK | 1 |
| Gonzales-Rosales, F | 1 |
| Walsh, D | 1 |
| Burkons, L | 1 |
| Burkons, J | 1 |
| Horvitz, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for famotidine and Adenocarcinoma
| Article | Year |
|---|---|
Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection.
Topics: Adenocarcinoma; Adenoma; Aged; Aged, 80 and over; Analysis of Variance; Famotidine; Female; Gastric | 2012 |
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Endoscopy, Gastrointestinal; Fam | 2005 |
2 other studies available for famotidine and Adenocarcinoma
| Article | Year |
|---|---|
Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Cimetidine; Famotidine; Female; Histamine H2 Antago | 1993 |
Chronic bleeding secondary to an unresectable duodenal adenocarcinoma controlled with sucralfate and famotidine.
Topics: Adenocarcinoma; Aged; Duodenal Neoplasms; Famotidine; Female; Gastrointestinal Agents; Gastrointesti | 1998 |